Skip to content
National Centre for Pharmacoeconomics

National Centre for Pharmacoeconomics

NCPE Ireland

  • Home
  • Who We Are
    • About Us
    • Current Vacancies
    • Glossary
Register for NCPE Events
  • Who We Are
    • Meet The Team
    • Current Vacancies
    • Monthly Updates
    • Contact Us
    • Glossary
  • Submission
    Process
    • Overview of the Drug Reimbursement Process
    • NCPE Recommendations
    • Process Flowchart
    • HTA Guidelines
    • Pre-submission meetings
    • Submission Templates
      • Rapid Review Template
      • Budget Impact Model Template
      • Full HTA Submission Template
      • New Medicine Horizon Scanning Template
  • Patients & Healthcare
    Professionals
    • Patients
      • Patient Submission Process Overview
      • Template, Registration form, Guidelines and Tip Sheet
      • Interpreting NCPE Recommendations
      • Patient Education
      • Useful Links
      • Glossary of Terms
    • Healthcare Professionals
  • International
    Collaborations
    • European Union HTA Regulation
      • EUnetHTA21
    • International Horizon Scanning Initiative
    • Beneluxa Initiative
    • Heads of Agency Group
    • Other collaborations
  • Research &
    Education
    • Research
      • Research Themes
      • Peer-Reviewed Publications
      • Conference Abstracts
      • Covid 19 Evidence Reviews
    • Education
  • Drugs
  • Other Technologies

Find Out More

The NCPE is an independent Health Technology Assessment agency, responsible for evaluating drug treatments for use in the Irish healthcare system.

Find Out More

We assess comparative effectiveness which tells us how well a medicine works compared to medicines that are currently used to treat a condition.

Find Out More

The NCPE assesses the cost effectiveness, or, value for money, of treatments for patients.

Find Out More

The NCPE engages with stakeholders, including clinicians and patients, before, throughout and after the assessment process.

Find Out More

The NCPE has a research function, with staff holding numerous teaching commitments, including those to patient-focused organisations.

Find Out More
  • SUBMISSION TEMPLATES
  • FIND A DRUG
  • FOR PATIENTS
News
  • First National Assessment of a drug with an EU Joint Clinical Assessment

    The NCPE Rapid Review of onasemnogene abeparvovec intrathecal (Itvisma®) is the first national assessment to be completed for a drug […]

  • Major milestone under the EU HTA Regulation: First Joint clinical assessment of benefit complete.

    Press release May 4th 2026   Major milestone under the EU HTA Regulation: First Joint clinical assessment of benefit complete. […]

  • Update to the Guidelines for Inclusion of Drug Costs in Pharmacoeconomic Evaluations v3.4

    Version 3.4 of the Guidelines for Inclusion of Drug Costs in Pharmacoeconomic evaluations was published 24 April 2026 and replaces […]

LATEST NCPE ADVICE

  • Pegcetacoplan (Aspaveli®) for glomerulopathy or glomerulonephritis. HTA ID 26039
  • Atogepant (Aquipta®) for acute treatment of migraine. HTA ID: 26038
  • Datopotamab deruxtecan (Datroway®) for triple-negative breast cancer. HTA ID: 26037
  • Acalabrutinib (Calquence®) for MCL. HTA ID: 25041
  • Cemiplimab (Libtayo®) in combination with platinum-based chemotherapy for NSCLC. HTA ID: 26036b
  • Linzagolix Choline (Yselty®). HTA ID: 23068

LATEST NCPE ADVICE

  • Pegcetacoplan (Aspaveli®) for glomerulopathy or glomerulonephritis. HTA ID 26039
  • Durvalumab (Imfinzi®). HTA ID: 25046
  • Trastuzumab Deruxtecan (Enhertu®). HTA ID: 25039
  • Atogepant (Aquipta®) for acute treatment of migraine. HTA ID: 26038
  • Daridorexant (Quviviq®) HTA ID: 25029
  • Rozanolixizumab (Rystiggo®). HTA ID: 26023
  • Terms & Conditions
  • Privacy Policy
  • Cookies Policy
  • Contact Us
© National Centre for Pharmacoeconomics, Ireland
  • LinkedIn
  • X
National Centre for Pharmacoeconomics, St James's Hospital, Emmet House, 138-140 Thomas St, Dublin 8, Ireland. D08 XN61